NORDIL: NORdic DILtiazem Study

NORDIL was a prospective, randomized, open blinded-endpoint, multicenter, parallel-group clinical trial in hypertensive patients aged 50-74 years in Norway and Sweden. 4200 participants were randomized to a diltiazem-based treatment strategy or a conventional strategy including diuretics and/or beta blockers with a DBP goal of < 90 or a 10% reduction from baseline. They found diltiazem to be as effective as conventional therapy in preventing the combined primary end point of all stroke, MI, and other CV death.

• Anna Dominiczak, University of Glasgow, Principal Investigator
• Sandosh Padmanabhan, University of Glasgow